Explore the history and impact of small molecules in this fascinating discussion. FidoCure’s Chief Medical Officer, Dr. Gerry Post interviews Dr. Cheryl London about their application in canine cancer treatment.

Dr. Cheryl London is a world-renowned expert in veterinary oncology and targeted cancer therapies at Tufts University. Her pioneering work began in 2000 when she collaborated with SUGEN to develop Palladia, one of the first targeted small molecule drugs approved for veterinary use, treating canine mast cell tumors driven by KIT mutations. 

Leave a Reply

Your email address will not be published. Required fields are marked *